SR-18292

CAS No. 2095432-55-4

SR-18292 ( SR-18292; SR 18292; SR18292 )

Catalog No. M17428 CAS No. 2095432-55-4

SR-18292 is a PPAR gamma coactivator-1α (PGC-1α) inhibitor, which increases PGC-1α acetylation, suppresses gluconeogenic gene expression and reduces glucose production in hepatocytes.

Purity : 98%

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 31 In Stock
5MG 50 In Stock
10MG 80 In Stock
25MG 170 In Stock
50MG 267 In Stock
100MG 425 In Stock
500MG 888 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SR-18292
  • Note
    Research use only, not for human use.
  • Brief Description
    SR-18292 is a PPAR gamma coactivator-1α (PGC-1α) inhibitor, which increases PGC-1α acetylation, suppresses gluconeogenic gene expression and reduces glucose production in hepatocytes.
  • Description
    SR-18292 is a PGC-1α inhibitor. SR-18292 reduces blood glucose, strongly increases hepatic insulin sensitivity, and improves glucose homeostasis in dietary and genetic mouse models of T2D.
  • Synonyms
    SR-18292; SR 18292; SR18292
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    HDAC
  • Recptor
    PGC-1α
  • Research Area
    Metabolic Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    2095432-55-4
  • Formula Weight
    366.51
  • Molecular Formula
    C23H30N2O2
  • Purity
    98%
  • Solubility
    DMSO : ≥ 100 mg/mL; 272.85 mM
  • SMILES
    CC(C)(C)N(Cc1ccc(C)cc1)CC(O)COc3cccc2nccc23
  • Chemical Name
    1-((1H-indol-4-yl)oxy)-3-(tert-butyl(4-methylbenzyl)amino)propan-2-ol

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Sharabi K,etal.Selective Chemical Inhibition of PGC-1α Gluconeogenic Activity Ameliorates Type 2 Diabetes.Cell. 2017 Mar 23;169(1):148-160.
molnova catalog
related products
  • Droxinostat

    Droxinostat (NS-41080) is a selective HDAC inhibitor with IC50 of 16.9, 2.47 and 1.46 uM for HDAC3, HDAC6 and HDAC8, respectively.

  • Encorafenib

    LGX818 is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.

  • Class I and IIB HDAC...

    Class I and IIB HDAC inhibitor 42 is a novel potent, selective class I and IIB inhibitor.